Therefore, we sought to investigate whether neoantigen vaccines could be further combined with Bev and anti-PD-1 antibody to build novel chemotherapy-free treatment strategy to improve the therapeutic efficacy of NSCLC. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.